Paclitaxel
- PDF / 170,061 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 145 Views
1 S
Paclitaxel Neutropenia: case report
A woman in her mid 70s [exact age at the time of reaction onset not stated] developed neutropenia during treatment with paclitaxel for cutaneous angiosarcoma with pulmonary metastases. The woman presented with painful macule on the scalp and weight loss at the age of 74 year in February 2015. Subsequently, multiple skin biopsies confirmed the diagnosis of cutaneous angiosarcoma. Therefore, between April 2015–May 2015, he had undergone successful brachytherapy. Thirteen months later (in June 2016), she developed a local recurrence, and she had received interferon-alpha and acitretin. Subsequently, she developed neutropenia and depression [aetiology not stated]. Therefore, in September 2016 treatment was discontinued. In January 2017, metastases were seen in the right lung. Hence, between February 2017–March 2017, she started receiving chemotherapy with paclitaxel 125 mg/m2 [Abraxane; route not stated] on days 1, 8 and 15 of a 28 day cycle. Subsequently, she developed neutropenia secondary to paclitaxel [time to reaction onset not stated]. Hence, between May 2017–July 2017, the woman’s paclitaxel dosage was reduced due to neutropenia [outcome not stated]. After two cycles a complete remission was achieved and paclitaxel was stopped. However, after four months a local relapse occurred. Therefore, low-dose paclitaxel was resumed and the regimen was maintained for more than a year. Recently, in view of extensive local progression the chemotherapy was switched to doxorubicin liposomal [pegylated liposomal doxorubicin] and she had a nearly complete remission. Andre F, et al. Combined nab-paclitaxel and irradiation for large cutaneous angiosarcoma of the face and scalp with pulmonary metastases. Journal der Deutschen Dermatologischen Gesellschaft 18: 754-757, No. 7, Jul 2020. Available from: URL: http://doi.org/10.1111/ddg.14127
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803498387
Reactions 29 Aug 2020 No. 1819
Data Loading...
